Nonantimicrobial Actions of Macrolides: Overview and Perspectives for Future Development
| Autor: | Jennifer A. Kricker, Clive P. Page, Fridrik Runar Gardarsson, Michael J. Parnham, Olafur Baldursson, Thorarinn Gudjonsson |
|---|---|
| Rok vydání: | 2021 |
| Předmět: |
Pharmacology
Coronavirus disease 2019 (COVID-19) SARS-CoV-2 business.industry medicine.drug_class Antibiotics COVID-19 Pulmonary disease Inflammation Azithromycin Anti-Bacterial Agents Epithelial Damage Broad spectrum Antibiotic resistance Immunology medicine Humans Molecular Medicine Macrolides medicine.symptom business medicine.drug |
| Zdroj: | Pharmacological Reviews |
| ISSN: | 1521-0081 0031-6997 |
| Popis: | Macrolides are among the most widely prescribed broad spectrum antibacterials, particularly for respiratory infections. It is now recognized that these drugs, in particular azithromycin, also exert time-dependent immunomodulatory actions that contribute to their therapeutic benefit in both infectious and other chronic inflammatory diseases. Their increased chronic use in airway inflammation and, more recently, of azithromycin in COVID-19, however, has led to a rise in bacterial resistance. An additional crucial aspect of chronic airway inflammation, such as chronic obstructive pulmonary disease, as well as other inflammatory disorders, is the loss of epithelial barrier protection against pathogens and pollutants. In recent years, azithromycin has been shown with time to enhance the barrier properties of airway epithelial cells, an action that makes an important contribution to its therapeutic efficacy. In this article, we review the background and evidence for various immunomodulatory and time-dependent actions of macrolides on inflammatory processes and on the epithelium and highlight novel nonantibacterial macrolides that are being studied for immunomodulatory and barrier-strengthening properties to circumvent the risk of bacterial resistance that occurs with macrolide antibacterials. We also briefly review the clinical effects of macrolides in respiratory and other inflammatory diseases associated with epithelial injury and propose that the beneficial epithelial effects of nonantibacterial azithromycin derivatives in chronic inflammation, even given prophylactically, are likely to gain increasing attention in the future. SIGNIFICANCE STATEMENT: Based on its immunomodulatory properties and ability to enhance the protective role of the lung epithelium against pathogens, azithromycin has proven superior to other macrolides in treating chronic respiratory inflammation. A nonantibiotic azithromycin derivative is likely to offer prophylactic benefits against inflammation and epithelial damage of differing causes while preserving the use of macrolides as antibiotics. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|